<SEC-DOCUMENT>0001193125-24-223726.txt : 20240923
<SEC-HEADER>0001193125-24-223726.hdr.sgml : 20240923
<ACCEPTANCE-DATETIME>20240923163429
ACCESSION NUMBER:		0001193125-24-223726
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240917
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240923
DATE AS OF CHANGE:		20240923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACADIA PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001070494
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				061376651
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50768
		FILM NUMBER:		241316608

	BUSINESS ADDRESS:	
		STREET 1:		12830 EL CAMINO REAL
		STREET 2:		SUITE 400
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-558-2871

	MAIL ADDRESS:	
		STREET 1:		12830 EL CAMINO REAL
		STREET 2:		SUITE 400
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d861822d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:acad="http://www.acadia-pharm.com/20240917" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_EntityRegistrantName" name="dei:EntityRegistrantName" contextRef="duration_2024-09-17_to_2024-09-17">ACADIA PHARMACEUTICALS INC</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-314">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-09-17_to_2024-09-17">0001070494</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="acad-20240917.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-09-17_to_2024-09-17"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001070494</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-09-17</xbrli:startDate> <xbrli:endDate>2024-09-17</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-325">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt:datemonthdayyearen" id="ixv-326">September&#160;17, 2024</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_EntityRegistrantName">Acadia Pharmaceuticals Inc.</span> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:stateprovnameen" id="ixv-327">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-328">000-50768</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-329">06-1376651</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-330">12830 El Camino Real</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-331">Suite 400</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-332">San Diego</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:stateprovnameen" id="ixv-333">California</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-334">92130</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-335">(858)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-336">558-2871</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N/A</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="ixv-337">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="ixv-338">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="ixv-339">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="ixv-340">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-341">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-342">ACAD</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:exchnameen" id="ixv-343">The Nasdaq Stock Market LLC</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-09-17_to_2024-09-17" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Termination of Stephen R. Davis as President and Chief Executive Officer and Resignation as Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;23, 2024, Acadia Pharmaceuticals Inc. (the &#8220;Company&#8221;) announced that Stephen R. Davis is departing the Company and will be succeeded by Catherine Owen Adams. On September&#160;17, 2024, the Board of Directors (the &#8220;Board&#8221;) of the Company agreed with Stephen R. Davis that he would be involuntarily terminated without Cause (as such term is defined in the Company&#8217;s Management Severance Benefit Plan (the &#8220;Severance Plan&#8221;)) from his position as President and Chief Executive Officer of the Company, effective as of September&#160;23, 2024 (the &#8220;Transition Date&#8221;). Mr.&#160;Davis resigned as a member of the Board, effective as of the Transition Date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Mr.&#160;Davis&#8217;s departure, he will receive severance benefits pursuant to the terms of the Severance Plan at the level of Chief Executive Officer, subject to his execution of a release of claims, including (i)&#160;cash severance equal to 1.5 times the sum of his base salary and target bonus in effect immediately prior to the Transition Date, (ii)&#160;a pro rata 2024 bonus based on his target bonus in effect immediately prior to the Transition Date, (iii) 12 months&#8217; accelerated equity award vesting and (iv) 18 months&#8217; COBRA premiums. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Transition Date, Mr.&#160;Davis and the Company entered into an Executive Transition Agreement (the &#8220;Transition Agreement&#8221;). Pursuant to the Transition Agreement, effective as of the Transition Date, Mr.&#160;Davis will continue as a consultant of the Company until the earlier of September&#160;23, 2025 and the date on which the Transition Agreement is terminated in accordance with its terms (the &#8220;Transition Period&#8221;), during which he will be entitled to continued vesting of his equity awards in accordance with the Company&#8217;s equity incentive plans such that Mr.&#160;Davis&#8217;s equity awards that would have vested from September&#160;23, 2025 to September&#160;23, 2026 shall instead vest during the Transition Period after taking into account the accelerated vesting provided under the Severance Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Receipt of the foregoing benefits are contingent upon Mr.&#160;Davis satisfying certain customary conditions as required by the Transition Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Transition Agreement is a summary only and is qualified in its entirety by reference to its full text, a copy of which is attached hereto as Exhibit 10.1. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Appointment of Catherine Owen Adams as Chief Executive Officer and Director </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On September&#160;20, 2024, the Board appointed Catherine Owen Adams, age 54, to serve as the Chief Executive Officer of the Company, including as the &#8220;principal executive officer&#8221; of the Company within the meaning of Rule <span style="white-space:nowrap">16a-1(f)</span> under the Securities Exchange Act of 1934, as amended, effective as of the Transition Date. In addition, effective as of the Transition Date, Ms.&#160;Owen Adams has been appointed to the Board as a Class&#160;III director to serve until the Company&#8217;s 2025 annual meeting of stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In her most recent role, Ms.&#160;Owen Adams served as Senior Vice President and General Manager, U.S., at Bristol Myers Squibb (&#8220;BMS&#8221;),&#160;a global biopharmaceutical company, where she led a $20&#160;billion commercial business, overseeing a large and diverse portfolio of promoted brands across Oncology, Cardiovascular, and Immunology from September 2019 to April 2024. In this role, she led over 3,000 employees and major product launches in lung cancer, obstructive hypertrophic cardiomyopathy, and psoriasis. Before this, Ms.&#160;Owen Adams held the position of Senior Vice President, Head of Major Markets at BMS,&#160;where she led commercial operations leading 6,000 employees across 19 countries in Europe, Japan, and Canada during BMS&#8217;s merger with Celgene. Under her leadership her teams achieved 9 new product launches in Oncology, <span style="white-space:nowrap">CAR-T,</span> Hematology, and Immunology, further solidifying her reputation as a global leader in the pharmaceutical space. Prior to her tenure at BMS, Ms.&#160;Owen Adams spent 25 years at Johnson&#160;&amp; Johnson (&#8220;J&amp;J&#8221;), where she held leadership roles across global, U.S., and European business units, with her last position being President, Janssen Immunology U.S. Over her career at J&amp;J, she gained deep experience in marketing, sales, market access, R&amp;D, and internal ventures across both the Pharmaceutical and Medical Technology sectors. Ms.&#160;Owen Adams began her career in R&amp;D and manufacturing at AstraZeneca after earning a BSc. in Pharmacy&#160;from the University of Manchester, becoming a qualified pharmacist and&#160;member of the Royal Pharmaceutical Society (MRPhS).&#160;Currently, Ms.&#160;Owen Adams serves on the board of directors of Agios Pharmaceuticals, Inc., a publicly held company, and AssistRx, a privately held company. Ms.&#160;Owen Adams was formerly on the board of directors and chair of the compensation committee for Optinose PLC, a public specialty pharmaceutical company, and was on the board of directors of Robert Wood Johnson University Hospitals, a <span style="white-space:nowrap">non-profit</span> organization. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with Ms.&#160;Owen Adams&#8217;s appointment as the Chief Executive Officer, the Company entered into an Employment Agreement with Ms.&#160;Owen Adams (the &#8220;Employment Agreement&#8221;), which provides for the following compensation: (i)&#160;an annual base salary of $900,000 per year, (ii)&#160;eligibility to receive an annual performance bonus with a target amount equal to 80% of the annual base salary, with the 2024 bonus <span style="white-space:nowrap">pro-rated</span> at target for Ms.&#160;Owen Adams&#8217;s service in 2024, (iii) a <span style="white-space:nowrap">sign-on</span> payment of $500,000, subject to a <span style="white-space:nowrap">pro-rata</span> clawback in the event Ms.&#160;Owen Adams resigns other than for Good Reason or her employment is terminated for Cause (as such term is defined in the Severance Plan) during the three years following the effective date of the Employment Agreement, and (iv)&#160;eligibility to participate in the Company&#8217;s annual equity incentive award grants beginning in 2025. Ms.&#160;Owen Adams will also receive certain perquisites and benefits consistent with those historically provided to the position of the Company&#8217;s Chief Executive Officer, as most recently described in the Compensation Discussion and Analysis section of the Company&#8217;s proxy statement for its 2024 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April&#160;26, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board also approved the following awards for Ms.&#160;Owen Adams, which were granted as of September&#160;23, 2024: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An award of stock options to purchase shares of the Company&#8217;s common stock with a target value of $3,250,000, which will vest 25% on the <span style="white-space:nowrap">one-year</span> anniversary of the grant date and in equal monthly installments over the three years thereafter, subject to Ms.&#160;Owen Adams continued employment through the applicable vesting dates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An award of performance share units with a target value of $3,250,000, which will vest over three years subject to the achievement of certain total shareholder return milestones relative to a subset of the Company&#8217;s peers, with payouts ranging from <span style="white-space:nowrap">0-150%</span> of target and subject to Ms.&#160;Owen Adams&#8217;s continued employment through the applicable vesting dates. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These awards were granted under the Company&#8217;s 2024 Inducement Plan and are subject to the terms and conditions set forth in the applicable notice of terms. Ms.&#160;Owen Adams will also be eligible to participate in the Severance Plan and the Company&#8217;s Amended and Restated Change in Control Severance Benefit Plan at the CEO level, the forms of which are filed as Exhibits 10.15 and 10.16, respectively, to the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K,</span> filed February&#160;28, 2024. The Company has also entered into its standard form of indemnification agreement with Ms.&#160;Owen Adams. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the Employment Agreement is a summary only and is qualified in its entirety by reference to its full text, a copy of which is attached hereto as Exhibit 10.2. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There is no arrangement or understanding between Ms.&#160;Owen Adams and any other person pursuant to which Ms.&#160;Owen Adams was selected as an officer or director, and there are no actual or proposed transactions between the Company and Ms.&#160;Owen Adams or any related person that would require disclosure under Item 404(a) of Regulation <span style="white-space:nowrap">S-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:5%"/>
<td style="width:92%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d861822dex101.htm">Executive Transition Agreement, dated September&#160;23, 2024, by and between the Company and Stephen R. Davis. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d861822dex102.htm">Employment Agreement, dated September&#160;23, 2024, by and between the Company and Catherine Owen Adams. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Acadia Pharmaceuticals Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: September&#160;23, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer J. Rhodes</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jennifer J. Rhodes</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Executive Vice President, Chief Legal Officer&#160;&amp; Secretary</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d861822dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>CADIA</SMALL> P<SMALL>HARMACEUTICALS</SMALL> I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXECUTIVE TRANSITION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Executive Transition Agreement (&#147;<B><I>Transition Agreement</I></B>&#148;), replaces and supersedes the Amended and Restated
Executive Employment Agreement dated September&nbsp;1, 2015 (the &#147;<B><I>Employment Agreement</I></B>&#148;) and all other employment or employment-related agreements or commitments entered into prior to the Effective Date of this Transition
Agreement (except as otherwise provided in this Transition Agreement), including the Management Severance Benefit Plan (the &#147;<B><I>Management Severance Plan</I></B>&#148;) and Participation Agreement thereunder dated February&nbsp;5, 2016 (the
&#147;<B><I>Participation Agreement</I></B>&#148; and, together with the Management Severance Plan, the &#147;<B><I>Severance Plan</I></B>&#148;) and the Amended and Restated Change in Control Severance Benefit Plan and Participation Agreement
thereunder dated July&nbsp;15, 2014 (collectively with the Severance Plan and the Employment Agreement, the &#147;<B><I>Prior Agreements</I></B>&#148;), by and among Acadia Pharmaceuticals Inc., a Delaware corporation, (the
&#147;<B><I>Company</I></B>&#148;), and Stephen R. Davis (the &#147;<B><I>Executive</I></B>&#148;). This Transition Agreement shall become effective on the &#147;Effective Date&#148; specified in Section&nbsp;5 below. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive have previously entered into the Prior Agreements and the Executive has provided extensive and
substantial service thereunder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive desire to provide continuity and efficiency in connection
with Executive&#146;s termination of employment as Chief Executive Officer and President of the Company and provide for a transition of employment and post-employment consulting services by the Executive; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and the Executive desire to supersede and replace the Prior Agreements with this Transition Agreement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TRANSITION AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>, <B>THEREFORE</B>, in consideration of the foregoing and the promises and covenants contained herein, and for other good and
valuable consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>TRANSITION AS
EMPLOYEE</B>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> <B><U>Transition Date</U></B>. The Executive and the Company agree that the Executive&#146;s employment as
Chief Executive Officer, President, officer, employee and member of the Board of Directors of the Company will cease effective September&nbsp;23, 2024 (the &#147;<B><I>Transition Date</I></B>&#148;). Executive agrees to resign from the Board of
Directors of the Company (the &#147;<B><I>Board</I></B>&#148;) and the respective boards of the Company&#146;s subsidiaries as of the Transition Date and to complete any required documents related thereto or necessary to effect such resignations.
The Executive&#146;s cessation of employment will constitute an Involuntary Termination (as such term is defined in the Severance Plan). </P> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> <B><U>Consulting Period</U></B>. The Executive shall serve as a consultant to
the Chief Executive Officer of the Company and the Board from the Transition Date until the earlier of September&nbsp;23, 2025 and the date on which the consulting arrangement is terminated in accordance with Section&nbsp;2 below (the
&#147;<B><I>Consulting Period</I></B>&#148;). During the Consulting Period, the Executive will perform reasonable services (not designed to create a conflict for the Executive)&nbsp;consistent with his expertise and experience with a maximum time
commitment of no more than 20% on average of Executive&#146;s historical service levels) to assist in the transition of leadership and perform such other duties as directed by the Company&#146;s Board or Chief Executive Officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> <B><U>Independent Contractor Relationship</U></B>. Executive&#146;s relationship with the Company during the Consulting Period
will be that of an independent contractor and nothing in this Agreement should be construed to create a partnership, joint venture, or employer-employee relationship. Executive is not the agent of the Company and is not authorized to make any
representation, contract, or commitment on behalf of the Company. Executive will not be entitled to any of the fringe benefits that the Company makes available exclusively to its employees, such as group insurance (other than COBRA health
continuation entitlement), profit-sharing, or retirement benefits. Executive will be solely responsible for all tax returns and payments required to be filed with or made to any federal, state, or local tax authority with respect to Executive&#146;s
performance of services and receipt of fees under this Agreement. The Company will regularly report amounts paid to Executive by filing Form 1099-MISC or other appropriate form with the Internal Revenue Service as required by law. Because Executive
is an independent contractor, the Company will not withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain worker&#146;s compensation insurance on Executive&#146;s behalf. Executive
accepts exclusive liability for complying with all applicable state and federal laws governing self-employed individuals, including obligations such as payment of taxes, social security, disability, and other contributions based on fees paid to
Executive, his/her agents, or employees under this Agreement, and agrees to indemnify and defend the Company against any and all such taxes or contributions, including penalties and interest. For the avoidance of doubt, during the Consulting Period,
Executive may be employed by, provide services to, or partner with other organizations and companies, so long as Executive&#146;s engagement in such activities would not be in breach of his obligations hereunder to the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>TERMINATION OF CONSULTING RELATIONSHIP</B>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.1</B> <B><U>Termination by the Company</U></B>. The Company may terminate the consulting relationship prior to September&nbsp;23, 2025
upon no less than thirty (30)&nbsp;days&#146; written notice to Executive (or immediately for Cause (as such term is defined in the Severance Plan)). In the event the Company terminates the consulting relationship without Cause, or due to his death
or disability, prior to September&nbsp;23, 2025, notwithstanding the terms of Company&#146;s Equity Incentive Plans, the Executive shall remain entitled to the continued equity vesting set forth in Section&nbsp;3.1 of this Transition Agreement. In
the event the Company terminates the consulting relationship for Cause, the Executive will not be entitled to any further benefits under the Transition Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.2</B> <B><U>Termination by Executive</U></B>. Executive may terminate the consulting relationship at any time upon 30 days prior written
notice to the Company. In the event the Executive terminates the consulting relationship prior to September&nbsp;23, 2025 for any reason the Executive will be entitled to no further benefits under this Transition Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>2.3</B> <B><U>Return of Company Property</U></B>. Upon termination of the Consulting
Period or earlier as requested by the Company, Executive will deliver to the Company any and all drawings, notes, memoranda, specifications, devices, formulas, and documents, together with all copies thereof, and any other material containing or
disclosing any Work Product, Third Party Information, or Proprietary Information of the Company. Executive shall be entitled to retain Company-owned computers, phones, and iPad; provided that the Company shall have the right to remove Company
information from such devices. Executive shall also be permitted to copy and retain his contacts list, calendars, personal correspondence and any information or documents reasonably necessary for the preparation of his applicable tax returns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>TRANSITION BENEFITS</B>. Provided that this Transition Agreement becomes effective as specified in Section&nbsp;5 hereof, the
Company shall provide Executive with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B><U>Severance Benefits</U></B>. In consideration of the
Executive&#146;s Involuntary Termination as an employee of the Company upon the Transition Date, the Executive shall be entitled following his Involuntary Termination to the severance payments and benefits set forth in Section&nbsp;2 of the
Participation Agreement in accordance with the terms and conditions of the Severance Plan (including, without limitation, the release requirement set forth therein, which the parties agree shall be satisfied by Executive&#146;s execution and <FONT
STYLE="white-space:nowrap">non-revocation</FONT> of this Agreement) and the Participation Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B><U>Continued Equity
Vesting</U></B>. For purposes of the vesting of any unvested equity awards granted to Executive under any of the Company&#146;s Equity Incentive Plans prior to the Transition Date that remain outstanding after application of the Severance Plan, as
set forth in Section&nbsp;3.1 above, the Company agrees that, provided this Transition Agreement becomes effective as specified in Section&nbsp;5 hereof, in accordance with the terms of the Company&#146;s Equity Incentive Plans, the Executive&#146;s
Continuous Service (as such term is defined in the Company&#146;s Equity Incentive Plans, as applicable) shall not be interrupted for so long as the Executive remains a consultant pursuant to this Transition Agreement. Accordingly, Executive&#146;s
equity awards shall continue to vest during Executive&#146;s service as a consultant and to be governed by the Equity Incentive Plans, as applicable, and subject to the terms of the applicable award agreements during the Consulting Period such that
Executive&#146;s equity awards that would have vested from September&nbsp;23, 2025 to September&nbsp;23, 2026 shall instead vest during the Consulting Period. For clarity, the vesting described in this Section&nbsp;3.2 shall be in addition to the
accelerated vesting provided under the Severance Plan, as set forth in Section&nbsp;3.1 above. Executive agrees that such continued vesting in accordance with Company&#146;s Equity Incentive Plan constitutes sufficient consideration for providing
the consulting services pursuant to this Transition Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>RESTRICTIVE COVENANTS</B>. Executive agrees that he will
continue to be subject to any existing confidentiality, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> or similar agreements between the Executive and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B><U><FONT STYLE="white-space:nowrap">Non-Competition</FONT></U></B>. Executive agrees that during the Consulting Period he will
not, either directly or through others, provide services to, own, manage, operate, join, control, finance or participate in the ownership, management, operation, control or financing of, or be connected as an officer, director, employee, partner,
principal, agent, representative, or consultant or hold any interest in any entity that competes with the business of the Company as in effect as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Transition Date, including for Neurocrine Biosciences, Abbvie, Otsuka Pharmaceutical Co., Ltd., Sunovion Pharmaceuticals Inc., IntraCellular Therapeutics, Anavex Life Sciences, Taysha Gene
Therapies, Neurogene, Soleno Therapuetics or Maplight Therapeutics, Inc. The foregoing does not prohibit Executive&#146;s ownership of less than five percent (5%) of the outstanding common stock of any company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B><U>Employee <FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></U></B>. Executive agrees that during the Consulting
Period and for twelve (12)&nbsp;months thereafter, Executive will not, either directly or through others, solicit or encourage or attempt to solicit or encourage any employee, independent contractor, or consultant of the Company to terminate his or
her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or entity. For the avoidance of doubt, it shall not be a violation of Executive&#146;s
<FONT STYLE="white-space:nowrap">non-solicitation</FONT> obligations to the Company for Executive to place (or cause to be place) general advertisements seeking employees or service providers or otherwise engage in job searches, in each case, so
long as such advertisements or searches are not targeted at employees, independent contractors or consultants of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.3</B>
<B><U>Client Non</U></B>-<B><U>Solicitation</U></B>. Executive agrees that during the Consulting Period, Executive will not, either directly or through others, (i)&nbsp;solicit or encourage or attempt to solicit or encourage any client or
prospective client of the Company to transact business with any entity that competes with the business of the Company as in effect during the Consulting Period or (ii)&nbsp;interfere with or damage any relationship between the Company and a client
or prospective client of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> <B><U><FONT STYLE="white-space:nowrap">Non-Disparagement</FONT></U></B>. Executive
agrees, during the Consulting Period and thereafter, not to disparage the Company and its affiliates and their predecessors, successors, and assigns, and/or the officers, directors, employees, stockholders, and agents of those entities, in any
manner likely to be harmful to its or their business, business reputation, or personal reputation. In consideration for the foregoing, the Company shall not, and shall instruct its directors and senior executive officers, not to disparage Executive.
Notwithstanding the foregoing (i)&nbsp;the Company and Executive will each respond accurately and fully to any question, inquiry or request for information, when required by legal process or when requested by a governmental, regulatory, or similar
body or entity or as reasonably necessary pursuant to any legal process between Executive and any of the foregoing parties; (ii)&nbsp;Executive may make statements in confidence to a professional advisor for the purpose of securing professional
advice; and (iii)&nbsp;the Company and Executive each may rebut false or disparaging statements made about the Company or Executive (as applicable) by any of the foregoing parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>4.5</B> <B>Inventions and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT></B>. Executive will be required to sign the
Company&#146;s Inventions and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement applicable to consultants, which shall be provided separately, as a condition of this Transition Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>RELEASE</B>. In exchange for the consideration provided to the Executive by this Transition Agreement that the Executive is not
otherwise entitled to receive, the Executive knowingly and voluntarily hereby generally and completely waives, terminates, cancels, releases and discharges forever the Released Parties (defined below) from any and all suits, actions, causes of
action, claims, allegations, rights, demands, entitlements, charges, liabilities and obligations, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that Executive (or Executive&#146;s heirs, executors, administrators, successors and assigns) has or may have, whether known, unknown or unforeseen, vested or contingent, that arise out of or are
in any way related to events, acts, conduct, or omissions occurring prior to and including the date that Executive signs this Transition Agreement. This general release includes, but is not limited to: (i)&nbsp;all claims arising out of or in any
way related to the Executive&#146;s employment with the Company or the separation of that employment; (ii)&nbsp;all claims relating to violations of any fair employment statute, law, rule, regulation, or ordinance or otherwise pertaining to
Executive&#146;s compensation or benefits from the Company, including but not limited to, salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe benefits, stock options, hours works, or any other interests in the
Company, whether or not paid under any compensation plan or arrangement; (iii)&nbsp;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv)&nbsp;all tort or other common law
claims, in each case, arising out of Executive&#146;s employment with the Company or the termination of that employment, including, but not limited to, claims for fraud, defamation, libel; slander; emotional distress, and discharge in violation of
public policy; and (v)&nbsp;all federal, state, and local statutory claims, including, but not limited to, claims for discrimination, harassment, retaliation, attorneys&#146; fees, or any other unlawful criterion or circumstance, including rights or
other claims arising under the Age Discrimination in Employment Act of 1967, the Older Workers Benefit Protection Act of 1990, violations of the Equal Pay Act, Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, the Americans
with Disabilities Act of 1991, the Employee Retirement Income Security Act of 1974 (&#147;<B><I>ERISA</I></B>&#148;), the Fair Labor Standards Act, the Worker Adjustment Retraining and Notification Act, the Family and Medical Leave Act, including
all amendments to any of the aforementioned acts (collectively, the &#147;<B><I>Released Matters</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">As used in this
Transition Agreement, the term &#147;<B><I>Released Parties</I></B>&#148; means the Company and its past and present directors, officers, employees, shareholders, members, partners, agents, attorneys, predecessors, successors, parent and subsidiary
entities, insurers, affiliates, and assigns (the &#147;<B><I>Released Parties</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">Executive further agrees to waive any and
all rights under the laws of any jurisdiction in the United States, or any other country, that limit a general release to those claims that are known or suspected to exist in Executive&#146;s favor as of the Effective Date. For the purpose of
implementing a full and complete release, Executive expressly acknowledges and agrees that this Release releases all claims existing or arising prior to Executive signing this Release which Executive has or may have against the Released Parties,
whether such claims are known or unknown and suspected or unsuspected by Executive and Executive forever waives all inquiries and investigations into any and all such claims. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.1</B> <B><U>Excluded Claims</U></B>: Notwithstanding the foregoing, the following are not included in the Released Matters: (i)&nbsp;any
rights or claims for indemnification the Executive may have pursuant to any written indemnification agreement with the Company or any subsidiary to which the Executive is a party, the charter, bylaws, or operating Transition Agreements of the
Company or any subsidiary, or under applicable law or any rights Executive may have under any directors&#146; and officers&#146; liability insurance policies maintained by the Company and its subsidiaries; (ii)&nbsp;any rights that are not waivable
as a matter of law; (iii)&nbsp;any claims for employee benefits under plans covered by ERISA to the extent any such claim may not lawfully be waived or for any payments or benefits under any Company plans that have vested according to the terms of
those </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
plans; (iv)&nbsp;any rights to vested equity awards issued by the Company or any rights as an equity stakeholder in the Company or (v)&nbsp;any claims arising from the breach of this Transition
Agreement (the &#147;<B><I>Excluded Claims</I></B>&#148;). The Executive hereby represents and warrants that, other than the Excluded Claims, the Executive is not aware of any claims the Executive has or might have against any of the Released
Parties that are not included in the Released Matters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.2</B> <B><U>Section 1542 Waiver</U></B>. In granting the release herein,
Executive expressly waives and relinquishes all rights and benefits afforded by Section&nbsp;1542 of the Civil Code of the State of California, and in so doing understands and acknowledges the significance of such specific waiver of
Section&nbsp;1542 that reads as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">&#147;A general release does not extend to claims that the creditor or releasing party does not
know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.&#148;<B> </B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Executive hereby expressly waives, relinquishes and forfeits all rights and accorded by the provisions of California Civil Code Section&nbsp;1542 and any
law of any jurisdiction of similar effect with respect to the Executive&#146;s release of claims hereby, and furthermore waives any rights that Executive might have to invoke such provisions now or in the future with respect to the Released Matters.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thus, notwithstanding the provisions of Section&nbsp;1542, and the purpose of implementing a full and complete release and discharge of the claims
released by this Release, Executive expressly acknowledges that this Release is intended to include in its effect, without limitation, all claims which Executive does not know or suspect to exist in Executive&#146;s favor at the time of execution
hereof arising out of or relating in any way to the subject matter of the actions referred to herein above and that this Release contemplates the extinguishment of any such claims </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.3</B> <B><U>Protected Activity</U></B>. Notwithstanding anything herein to the contrary, this Release shall not: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>5.3.1</B> Prevent Executive from discussing or disclosing information about unlawful acts in the workplace, such as harassment or
discrimination, or any other acts that Executive has reason to believe are unlawful; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>5.3.2</B> Preclude Executive from disclosing or
discussing information lawfully acquired about wages, hours or other terms and conditions of employment if used for purposes protected by Section&nbsp;7 of the National Labor Relations Act such as joining or forming a union, engaging in collective
bargaining or engaging in other concerted activity for the mutual aid or protection of employees; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman"><B>5.3.3</B> Limit Executive&#146;s
rights under applicable law to initiate communications directly with, provide information to, respond to any inquiries from, or report possible violations of law or regulation to any governmental entity or self-regulatory authority, or to file a
charge with or participate in an investigation conducted by any governmental entity or self-regulatory authority, and Executive does not need any Released Party&#146;s permission to do so. In addition, it is understood that this Release shall not
require Executive to notify any Released </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Party of a request for information from any governmental entity or self-regulatory authority that is not directed to the Company or of Executive&#146;s decision to file a charge or complaint with
or participate in an investigation conducted by any governmental entity or self-regulatory authority. Notwithstanding the foregoing, Executive recognizes that, in connection with the provision of information to any governmental entity or
self-regulatory authority, Executive must inform such governmental entity or self-regulatory authority that the information Executive is providing is confidential. Despite the foregoing, Executive is not permitted to reveal to any third party,
including any governmental entity or self-regulatory authority, information Executive came to learn during Executive&#146;s service to the Company that is protected from disclosure by any applicable privilege, including but not limited to the
attorney-client privilege or attorney work product doctrine. The Company does not waive any applicable privileges or the right to continue to protect its privileged attorney-client information, attorney work product, and other privileged
information. In addition, Executive agrees to waive Executive&#146;s right to recover monetary damages in connection with any charge, complaint or lawsuit pertaining to the Released Matters filed by Executive or anyone else on Executive&#146;s
behalf (whether involving a governmental entity or not); provided that Executive is not agreeing to waive, and this Release shall not be read as requiring Executive to waive, any right Executive may have to receive any bounty or monetary award from
any governmental entity or regulatory or law enforcement authority in connection with information provided to any governmental entity or other protected &#147;whistleblower&#148; activity. In addition, it is understood that Executive shall respond
accurately and fully to any question, inquiry or request for information when required by legal process or as reasonably necessary pursuant to any legal process between Executive and any of the parties named herein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>5.4</B> <B><U>ADEA Waiver</U></B>. The Executive acknowledges and agrees that Executive<B> </B>has read this Release in its entirety and
that this Release is a general release of all known and unknown claims, including claims under the Age Discrimination in Employment Act. The Executive also acknowledges that the consideration given for the Executive&#146;s releases in this
Transition Agreement is in addition to anything of value to which the Executive was already entitled. The Executive is advised by this writing that: (i)&nbsp;the Executive&#146;s waiver and release does not apply to any claims that may arise after
the Executive signs this Transition Agreement; (ii)&nbsp;the Executive should consult with an attorney prior to executing this release; (iii)&nbsp;the Executive has <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days within which to
consider this release (although the Executive may choose to voluntarily execute this release earlier); (iv) the Executive has seven (7)&nbsp;days following the execution of this release to revoke this Transition Agreement; and (v)&nbsp;this
Transition Agreement will not be effective until the eighth day after the Executive signs this Transition Agreement, provided that the Executive has not earlier revoked this Transition Agreement (the &#147;<B><I>Effective Date</I></B>&#148;). The
Executive will not be entitled to receive any of the benefits specified by this Transition Agreement unless and until it becomes effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>ATTORNEYS FEES</B>. The Company shall reimburse the Executive for (or pay directly) his reasonable attorneys&#146; fees and costs
incurred in the review, drafting and negotiation of this Transition Agreement and any ancillary documents, up to a cap of $30,000. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>IRC 409A. </B>The compensation payable to Executive hereunder and under the Management Severance Plan is intended to comply with
Section&nbsp;409A of the Internal Revenue Code. Should any provision of this Agreement or the Management Severance Plan be determined to be in violation of said Section&nbsp;409A, the parties will negotiate in good faith such modifications as may be
deemed necessary in order to so comply with the intention of preserving the original economic intent of the parties hereto to the maximum possible. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>ENTIRE AGREEMENT</B>. This Transition Agreement constitutes the complete, final
and exclusive embodiment of the entire agreement between the Executive and the Company with regard to this subject matter; provided that this Transition Agreement does not supersede or amend any existing confidentiality or similar agreement between
the Executive and the Company. It is entered into without reliance on any promise or representation, written or oral, other than those expressly contained herein, and it supersedes any other such promises, warranties or representations. This
Transition Agreement may not be modified or amended except in a writing signed by both the Executive and the Chairman of the Board of Directors of the Company. The failure to enforce any breach of this Transition Agreement shall not be deemed to be
a waiver of any other or subsequent breach. For purposes of construing this Transition Agreement, any ambiguities shall not be construed against either party as the drafter. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>SUCCESSORS AND ASSIGNS</B>. This Transition Agreement shall bind the heirs, personal representatives, successors, assigns,
executors, and administrators of each party, and inure to the benefit of each party, its agents, directors, officers, employees, servants, heirs, successors and assigns. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>APPLICABLE LAW</B>. This Transition Agreement shall be deemed to have been entered into and shall be construed and enforced in
accordance with the laws of the State of California as applied to contracts made and to be performed entirely within California. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>SEVERABILITY</B>. If a court or arbitrator of competent jurisdiction determines that any term or provision of this Transition
Agreement is invalid or unenforceable, in whole or in part, the remaining terms and provisions hereof shall be unimpaired. Such court or arbitrator will have the authority to modify or replace the invalid or unenforceable term or provision with a
valid and enforceable term or provision that most accurately represents the parties&#146; intention with respect to the invalid or unenforceable term or provision. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>COUNTERPARTS</B>. This Transition Agreement may be executed in two counterparts, each of which shall be deemed an original, all
of which together shall constitute one and the same instrument. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>SECTION HEADINGS</B>. The section and paragraph headings
contained in this Transition Agreement are for reference purposes only and shall not affect in any way the meaning or interpretation of this Transition Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>PHOTOCOPIES</B>. A photocopy of this executed Transition Agreement shall be as valid, binding, and effective as the original
Transition Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Signature page follows</I>) </P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the parties have executed this Executive Transition Agreement as
of the date last written below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="78%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>ACADIA PHARMACEUTICALS INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Rhodes</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Jennifer Rhodes</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Executive Vice President, Chief Legal Officer, and Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>EXECUTIVE:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stephen R. Davis</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stephen R. Davis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Date:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">September&nbsp;22, 2024</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Executive Transition Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d861822dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">EXECUTION VERSION </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EMPLOYMENT
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Executive Employment Agreement (the &#147;<U>Agreement</U>&#148;) is made and entered into effective as of
September&nbsp;23, 2024 (the &#147;<U>Effective Date</U>&#148;) by and between Acadia Pharmaceuticals Inc., a Delaware Corporation (the &#147;<U>Company</U>&#148;), and Catherine Owen Adams (&#147;<U>Executive</U>&#148;). The Company and Executive
are hereinafter collectively referred to as the &#147;Parties&#148;, and individually referred to each as a &#147;Party&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>WHEREAS</B>, the Company and Executive desire to enter into this Agreement on the terms set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>NOW</B>,
<B>THEREFORE</B>, in consideration of the mutual promises and covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B> <B>Employment</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.1</B> The Company hereby agrees to employ Executive, and Executive hereby accepts employment by the Company, upon the terms and conditions
set forth in this Agreement for the period beginning on the Effective Date. Executive shall be an <FONT STYLE="white-space:nowrap">at-will</FONT> employee. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.2</B> Executive shall serve as Chief Executive Officer of the Company, and shall have the normal duties, responsibilities and authority of
such office, unless otherwise determined from time to time by the Company&#146;s Board of Directors (the &#147;<U>Board</U>&#148;). Executive shall do and perform all services, acts, or responsibilities necessary or advisable to carry out the job
duties of Chief Executive Officer of the Company as assigned by the Company, provided, however, that at all times during her employment Executive shall be subject to the direction and policies from time to time established by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.3</B> In connection with Executive serving as Chief Executive Officer of the Company, Executive shall be appointed to the Board. Executive
agrees that if Executive&#146;s employment is terminated for any reason whatsoever, Executive will resign, at the Company&#146;s request, from the Board and from any other positions Executive has as an officer or director of any of the
Company&#146;s direct or indirect subsidiaries and any other entity in which the Executive is serving as an officer or director at the request of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.4</B> Executive shall be based primarily in the Company&#146;s offices located in Princeton, New Jersey and San Diego, California, with
business travel as reasonably required to perform Executive&#146;s duties hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.</B> <B>Loyal and Conscientious Performance</B>.
During her employment with the Company, Executive shall devote sufficient energy, abilities and productive time to the proper and efficient performance of this Agreement necessary to properly carry out the duties of Chief Executive Officer;
provided, that, Executive is permitted to serve on the board of directors of one or more outside entities during her employment with the Company, subject to the approval of the Chair of the Board. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B> <B>Compensation</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.1</B> <B>Base Salary</B>. Beginning with the Effective Date of this Agreement, the Company shall pay Executive a salary (the &#147;<U>Base
Salary</U>&#148;) of $900,000 per year, subject to standard payroll deductions and withholdings, and payable twice monthly in accordance with the Company&#146;s normal payroll practices. The Base Salary may be subject to annual increases by the
Board based on any recommendations from the Compensation Committee of the Board (the &#147;<U>Compensation Committee</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.2</B> <B><FONT STYLE="white-space:nowrap">Sign-On</FONT> Equity</B>. On the Effective Date of this Agreement, the Company shall grant
Executive the following equity awards under the Company&#146;s 2024 Inducement Plan (the &#147;<U>2024 Plan</U>&#148;): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.2.1</B> An
award of stock options to purchase shares of the Company&#146;s common stock with a target value of $3,250,000. The option exercise price will equal the closing price of the Company&#146;s common stock on the Effective Date. The number of stock
options granted to Executive shall be equal to the target value divided by the product of the Black-Scholes factor and the Company&#146;s 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> volume-weighted average price ending on (and including)
the Effective Date.&nbsp;The Black-Scholes factor is equal to the Black-Scholes value of one stock option on the grant date divided by the closing price on such date. The terms and conditions of this grant of stock options shall be set forth in a
separate stock option award agreement provided to you and shall be governed by the 2024 Plan, and the options will be subject to the service vesting conditions set forth in the stock option award agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.2.2</B> An award of performance-based restricted stock units (&#147;<U>PSUs</U>&#148;) with a target value of $3,250,000. The number of
PSUs granted to Executive shall be equal to the target value divided by the product of the Monte Carlo factor and the Company&#146;s 30 <FONT STYLE="white-space:nowrap">trading-day</FONT> volume-weighted average price ending on (and including) the
Effective Date.&nbsp;The Monte Carlo factor is equal to the Monte Carlo value of one PSU on the grant date divided by the closing price on such date. The terms and conditions of this grant of PSUs shall be set forth in a separate PSU award agreement
provided to you and shall be governed by the 2024 Plan, and the PSUs will be subject to the performance and service vesting conditions set forth in the PSU award agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.3</B> <B>Annual Equity</B>. Beginning in 2025, Executive will be eligible to participate in the annual equity grants under the 2024 Plan
(or an applicable successor plan) that are made available to the Company&#146;s executive officers, subject to Executive&#146;s continued employment through the date on which such awards are granted. The 2025 grants will not be <FONT
STYLE="white-space:nowrap">pro-rated</FONT> for Executive&#146;s service in 2024. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.4</B> <B>Other Compensation and Benefits</B>. In
addition to the Base Salary payable to Executive hereunder, the Executive shall be entitled to the following benefits: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.4.1</B> All
benefits to which all other executive officers of the Company generally are entitled as determined by the Board, on terms comparable thereto, including but not limited to, participation in any and all 401(k) plans, bonus and incentive payment
programs, group life insurance policies and plans, medical, health, dental and disability insurance policies and plans, and the like, which may be maintained by the Company for the benefit of its Executive officers. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.4.2</B> Executive&#146;s target bonus shall be 80% of Base Salary. The actual annual
bonus, if any, will be determined by the Board following a recommendation from the Compensation Committee based on the Executive&#146;s and the Company&#146;s performance for the prior year and shall range from
<FONT STYLE="white-space:nowrap">0-150%</FONT> of the target bonus. Executive must be an employee of the Company on the date upon which bonuses are paid to be eligible for such a bonus. Executive will not receive a prorated bonus in the event
Executive resigns or is terminated prior to the date upon which bonuses are paid. The Board, based on recommendations from the Compensation Committee, shall have the right to change the Executive&#146;s target bonus. The 2024 bonus will be <FONT
STYLE="white-space:nowrap">pro-rated</FONT> at target for Executive&#146;s service in 2024. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.4.3</B> Twenty-five (25)&nbsp;days of
vacation per year, which shall accrue monthly beginning with the effective date of this Agreement consistent with the Company&#146;s policies. If the Executive does not utilize the entire twenty-five (25)&nbsp;days of annual vacation in a given
year, she may carry over days to the extent permitted under the Company&#146;s policies. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman"><B>3.4.1</B> The Company shall provide Executive
with a single, <FONT STYLE="white-space:nowrap">lump-sum</FONT> <FONT STYLE="white-space:nowrap">sign-on</FONT> cash payment of $500,000 (the <FONT STYLE="white-space:nowrap">&#147;Sign-on</FONT> Payment&#148;). In the event that Executive&#146;s
employment is terminated by the Company for Cause or by Executive other than for Good Reason, but not including termination of employment due to death or disability, on or before the second anniversary of the Effective Date, Executive shall repay
the Company a <FONT STYLE="white-space:nowrap">pro-rated</FONT> portion of the <FONT STYLE="white-space:nowrap">Sign-on</FONT> Payment based on Executive&#146;s time served with the Company, which shall be calculated by multiplying the <FONT
STYLE="white-space:nowrap">Sign-on</FONT> Payment by a fraction, the numerator of which is the number of months between Executive&#146;s termination and the second anniversary of the Effective Date, and the denominator of which is 24. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.5</B> <B>Reimbursements</B>. The Company shall reimburse Executive for all reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by her in the course of performing her duties under this Agreement, which are consistent with the Company&#146;s policies in effect from time to time with respect to travel,
entertainment and other business expenses, subject in all cases to the Company&#146;s requirements with respect to reporting and documentation of such expenses pursuant to Company policy. However, Executive shall generally be responsible for housing
and transportation expenses in San Diego and her travel to and from Princeton and San Diego. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.6</B> <B>Withholding</B>. All of
Executive&#146;s compensation shall be subject to customary federal and state withholding taxes and any other employment taxes as are commonly required to be collected or withheld by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.7</B> <B>Severance Benefits</B>. Executive will be eligible to participate in the Company&#146;s Management Severance Benefit Plan and the
Company&#146;s Change in Control Severance Benefit Plan (collectively, the &#147;<U>Severance Plans</U>&#148;) at the stated Chief Executive Officer level; provided, that the term &#147;Good Reason&#148; as it applies to Executive under the
Management Severance Benefit Plan shall have the meaning set forth in the Change in Control Severance Benefit Plan. Executive&#146;s participation agreement for such plans will be provided separately. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B> <B>Termination</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.1</B> <B>Termination for Cause</B>. The Company shall terminate this Agreement for Cause (as defined herein) by delivery of written notice
to Executive specifying the cause or causes relied upon for such termination. If Executive&#146;s employment under this Agreement is terminated by the Company for Cause before the last day of any calendar month, Executive shall be entitled to
receive as compensation for such calendar month, only the Base Salary set forth in Section&nbsp;3.1 prorated to the date of termination on the basis of a <FONT STYLE="white-space:nowrap">30-day</FONT> calendar month. The term
&#147;<U>Cause</U>&#148; as used in this Agreement shall have the same meaning ascribed to such term in the Severance Plans, as applicable. Any notice of termination given pursuant to Section&nbsp;4.1 shall effect termination as of the date
specified in such notice, or in the event no such date is specified, on the last day of the month in which such notice is delivered. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.2</B> <B>Termination Without Cause</B>. The Company may voluntarily terminate this Agreement without Cause by giving written notice to
Executive. Any such notice shall specify the exact date of termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.3</B> <B>Termination by Executive</B>. Executive may
voluntarily terminate this Agreement upon sixty (60)&nbsp;days&#146; written notice (subject to any other notice requirements pursuant to the applicable Severance Plan) of such termination submitted to the Board, and in such event Executive shall be
entitled to receive all amounts due to her through the date of termination. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.4</B> This Employment Agreement is a personal services
contract whereby the Company is engaging the services of Executive. By entering into this Agreement, the Company is relying on Executive performing her services for the Company throughout the entire term of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B> <B>Section</B><B></B><B>&nbsp;409A</B>. Notwithstanding anything set forth in this Agreement to the contrary, any payments and
benefits provided pursuant to this Agreement which constitute &#147;deferred compensation&#148; within the meaning of the Treasury Regulations issued pursuant to Section&nbsp;409A of the Internal Revenue Code of 1986, as amended
(&#147;<U>Section</U><U></U><U>&nbsp;409A</U>&#148;) shall not commence until Executive has incurred a &#147;separation from service&#148; (as such term is defined in the Treasury Regulation
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-1(h)</FONT> (&#147;<U>Separation From Service</U>&#148;), unless the Company reasonably determines that such amounts may be provided to Executive without causing Executive to incur the additional
20% tax under Section&nbsp;409A. It is intended that all of the payments payable under this Agreement satisfy, to the greatest extent possible, the exemptions from the application of Code Section&nbsp;409A provided under Treasury <FONT
STYLE="white-space:nowrap">Regulations&nbsp;1.409A-1(b)(4),</FONT> <FONT STYLE="white-space:nowrap">1.409A-1(b)(5)</FONT> and <FONT STYLE="white-space:nowrap">1.409A-1(b)(9),</FONT> and this Agreement will be construed to the greatest extent
possible as consistent with those provisions, and to the extent not so exempt, this Agreement (and any definitions hereunder) will be construed in a manner that complies with Section&nbsp;409A. For purposes of Section&nbsp;409A (including, without
limitation, for purposes of Treasury Regulation <FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-2(b)(2)(iii)),</FONT> Executive&#146;s right to receive any installment payments under this Agreement shall be treated as a right to receive a
series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this Agreement or the Severance Agreements, if
Executive is deemed by the Company at the time of Executive&#146;s Separation from Service to be a &#147;specified employee&#148; for purposes of Code Section&nbsp;409A(a)(2)(B)(i), and if any of the payments
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
upon Separation from Service set forth herein and/or under any other agreement with the Company are deemed to be &#147;deferred compensation&#148;, then to the extent delayed commencement of any
portion of such payments is required in order to avoid a prohibited distribution under Code Section&nbsp;409A(a)(2)(B)(i) and the related adverse taxation under Section&nbsp;409A, such payments shall not be provided to Executive prior to the
earliest of (i)&nbsp;the expiration of the <FONT STYLE="white-space:nowrap">six-month</FONT> period measured from the date of Executive&#146;s Separation from Service with the Company, (ii)&nbsp;the date of Executive&#146;s death or (iii)&nbsp;such
earlier date as permitted under Section&nbsp;409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section&nbsp;409A(a)(2)(B)(i) period, all payments deferred pursuant to this
paragraph shall be paid in a lump sum to Executive, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B> <B>Death or Disability During the Term of Employment</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.1</B> This Agreement shall terminate without notice upon the date of Executive&#146;s death or the date when Executive becomes
&#147;completely disabled&#148; as that term is defined in Section&nbsp;6.4. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.2</B> In the event of Executive&#146;s death, all rights
of Executive to compensation hereunder shall automatically terminate immediately upon her death, except that Executive&#146;s heirs, personal representatives or estate shall be entitled to any unpaid portion of her salary and accrued benefits earned
up to the date of her death. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.3</B> In the event Executive is disabled, Executive shall be entitled to receive such disability
benefits as would apply to other executive officers in the Company, subject to the terms and conditions of any such Company disability program and Executive&#146;s equity awards will be treated in accordance with their terms. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>6.4</B> The term &#147;completely disabled&#148; as used in this Agreement shall mean the inability of Executive to perform her duties under
this Agreement because she has become permanently disabled within the meaning of any policy and disability income insurance covering Executives of the Company then in force. In the event the Company has no policy of disability income insurance
covering Executives of the Company in force when Executive becomes disabled, the term &#147;completely disabled&#148; shall mean the inability of Executive to perform her normal and customary duties under this Agreement for a total of six
(6)&nbsp;consecutive months by reason of any incapacity, physical or mental, based upon medical advice or an opinion provided by a licensed physician acceptable to the Board, determines to have incapacitated Executive from satisfactorily performing
all of her usual services for the Company during the foreseeable future. The action of the Board shall be final and binding and the date such action is taken shall be the date of such complete disability for purposes of this Agreement, and upon such
date this Agreement shall become null and void and of no further force and effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B> <B>Restrictive Covenants</B>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.1</B> <B><FONT STYLE="white-space:nowrap">Non-Solicitation</FONT></B>. Executive agrees that during the period of her employment with the
Company and for twelve (12)&nbsp;months after the date Executive&#146;s employment is terminated for any reason, Executive will not, either directly or through others, solicit or encourage or attempt to solicit or encourage any employee, independent
contractor, or consultant of the Company to terminate her or her relationship with the Company in order to become an employee, consultant or independent contractor to or for any other person or entity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.2</B> <B>Inventions and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT></B>.
Executive will be required to sign the Company&#146;s Inventions and <FONT STYLE="white-space:nowrap">Non-Disclosure</FONT> Agreement, which shall be provided separately, as a condition of her employment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>7.3</B> <B>Trade Secrets and Confidential Information from Current or Prior Employers</B>. Executive agrees that she will not bring or use
any confidential information or trade secrets from current or former employers during her employment with the Company. Executive agrees and acknowledges that she has notified the Company of any and all
<FONT STYLE="white-space:nowrap">non-compete,</FONT> <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality or other restrictive agreements with such current or former employers that could impact her employment with the Company.
Prior to the Effective Date, Executive will provide the Company with copies of any such agreements. Executive agrees that she has reviewed the duties and responsibilities of her new position and that no contractual or other restrictions will prevent
Executive from performing those duties. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B> <B>Assignment and Binding Effect</B>. This Agreement shall be binding upon and inure to
the benefit of Executive and Executive&#146;s heirs, executors, administrators, estate, beneficiaries, and legal representatives. Neither this Agreement nor any rights or obligations under this Agreement shall be assignable by either party without
the prior express written consent of the other party. This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns and legal representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B> <B>Notices</B>. All notices or demands of any kind required or permitted to be given by the Company or Executive under this Agreement
shall be given in writing and shall be personally delivered (and receipted for) or sent by facsimile (with confirmation of receipt), or sent by recognized commercial overnight courier, or mailed by certified mail, return receipt requested, postage
prepaid, addressed as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Attention: General Counsel </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Acadia Pharmaceuticals Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">3611
Valley Centre Drive, Suite&nbsp;300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">San Diego, CA&nbsp;92130 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Fax </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to Executive: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">At the then-current address on file with Human Resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any such written notice shall be deemed received when personally delivered or upon receipt in the event of facsimile or overnight courier, or
three (3)&nbsp;days after its deposit in the United States mail by certified mail as specified above. Either Party may change its address for notices by giving notice to the other Party in the manner specified in this section. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B> <B>Choice of Law</B>. This Agreement is made in Princeton, New Jersey. This
Agreement shall be construed and interpreted in accordance with the internal laws of the State of New Jersey. Each of the parties hereto agrees to the exclusive jurisdiction of the state and federal courts located in the State of New Jersey for any
and all actions between the parties. Subject to the provisions of Section&nbsp;19, any controversy or claim arising out of or relating to this Agreement or breach thereof, whether involving remedies at law or in equity, shall be adjudicated in
Princeton, New Jersey. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>Integration</B>. This Agreement contains the entire agreement of the parties relating to the subject
matter of this Agreement, and supersedes all prior oral and written employment agreements or arrangements between the Parties. This Agreement cannot be amended or modified except by a written agreement signed by Executive and the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>Waiver</B>. No term, covenant or condition of this Agreement or any breach thereof shall be deemed waived, except with the
written consent of the Party against whom the waiver is claimed, and any waiver of any such term, covenant, condition or breach shall not be deemed to be a waiver of any preceding or succeeding breach of the same or any other term, covenant,
condition or breach. No failure to exercise, delay in exercising, or single or partial exercise of any right, power or remedy by either party hereto shall constitute a waiver thereof or shall preclude any other or further exercise of the same or any
other right, power or remedy. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>Severability</B>. The unenforceability, invalidity, or illegality of any provision of this
Agreement shall not render any other provision of this Agreement unenforceable, invalid or illegal. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B> <B>Interpretation;
Construction</B>. The headings set forth in this Agreement are for convenience only and shall not be used in interpreting this Agreement. The Parties acknowledge that each Party and its counsel has reviewed and revised, or had an opportunity to
review and revise, this Agreement, and the normal rule of construction to the effect any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>Attorneys&#146; Fees</B><B></B>. In any controversy or claim arising out of or relating to this Agreement or the breach thereof,
which results in legal action, proceeding or arbitration, the prevailing party in such action, as determined by the court or arbitrator, shall be entitled to recover reasonable attorneys&#146; fees and costs incurred in such action. The Company
shall reimburse Executive for up to $20,000 of reasonable legal fees incurred in connection with negotiation of this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B>
<B>Counterparts</B>. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall together constitute an original thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>Representations and Warranties</B>. Executive represents and warrants that she is not restricted or prohibited, contractually or
otherwise, from entering into and performing each of the terms and covenants contained in this Agreement, and that her execution and performance of this Agreement will not violate or breach any other agreement between Executive and any other person
or entity. Executive affirms that she has no agreement with any other party that would preclude her compliance with any obligations under this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>18.</B> <B>Preservation of Property</B>. Executive will exercise reasonable care,
consistent with good business judgment to preserve in good working order, subject to reasonable wear and tear from authorized usage, and to prevent loss of, any equipment, instruments or accessories of the Company in her custody for the purpose of
conducting the business of the Company. Upon request, Executive will promptly surrender the same to the Company at the conclusion of her employment, or if not surrendered, Executive will account to the Company to its reasonable satisfaction as to
the present location of all such instruments or accessories and the business purpose for their placement at such location. At the conclusion of Executive&#146;s employment with the Company, she agrees to return such instruments or accessories to the
Company or to account for same to the Company&#146;s reasonable satisfaction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>19.</B> <B>Arbitration</B><B></B>. Any controversy or
claim arising out or relating to this Agreement, or the breach hereof, or arising out of or relating to the rights, duties or obligations of the Company or of Executive shall be settled by binding arbitration conducted in Princeton, New Jersey in
accordance with, and by an arbitrator appointed pursuant to the rules of the American Arbitration Association in effect at the time, and the judgment upon the award rendered pursuant thereto shall be in writing and may be entered in any court having
jurisdiction, and all rights or remedies of the Company and of the Executive to the contrary are hereby expressly waived. The Company shall pay the arbitration fees and costs for such arbitrator. Notwithstanding the foregoing, Executive agrees that
unique and proprietary knowledge and information has been and will be possessed by, disclosed to, or developed by Executive in the course of Executive&#146;s employment with the Company, that the provisions set forth in Section&nbsp;7 are reasonable
and necessary to protect the Company&#146;s legitimate business interests, and that they will not unreasonably interfere with Executive&#146;s ability to earn a living following Executive&#146;s separation from the Company. Accordingly, Executive
agrees that, in the event Executive breaches or threatens to breach these <FONT STYLE="white-space:nowrap">non-solicitation</FONT> provision, such breach will cause irreparable harm and injury to the Company and will leave the Company with no
adequate remedy at law, and (i)&nbsp;the Company may seek equitable relief, without the necessity of posting a bond, in addition to monetary damages and any other appropriate relief; and (ii)&nbsp;the Company will be entitled to its reasonable
attorneys&#146; fees and costs incurred in enforcing this provision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(<I>Signature page follows</I>) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, the Parties have executed this Agreement as of the Effective
Date. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Acadia Pharmaceuticals Inc.</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">EXECUTIVE:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Rhodes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Catherine Owen Adams</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Name:&#8201;&#8202;Jennifer Rhodes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Catherine Owen Adams</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-3.00em; font-size:10pt; font-family:Times New Roman">Title:&#8194;&#8201;&#8202;Executive Vice President, Chief Legal Officer, and Secretary</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page to Executive Employment Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>acad-20240917.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 12:31:02 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:acad="http://www.acadia-pharm.com/20240917"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.acadia-pharm.com/20240917"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20240917_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acad-20240917_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>acad-20240917_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 12:31:03 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>acad-20240917_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 9/24/2024 12:31:03 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="acad-20240917.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45875517534240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 17, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACADIA PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001070494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 17,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1376651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12830 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">558-2871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACAD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M/UY_ 5!+ 0(4 Q0    ( $Z$-UD'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 3H0W68NOO_?O
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ 3H0W69E<G",0!@  G"<  !,              ( !S0$  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    " !.A#=961KHF&H$   Y$0  &
M            @($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ 3H0W69^@&_"Q @  X@P   T              ( !K@P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    " !.A#=9EXJ[',     3 @  "P
M    @ &*#P  7W)E;',O+G)E;'-02P$"% ,4    " !.A#=9'#AEZC\!   \
M @  #P              @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ 3H0W620>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3H0W6660>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d861822d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>acad-20240917.xsd</File>
    <File>acad-20240917_lab.xml</File>
    <File>acad-20240917_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d861822d8k.htm">d861822d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d861822d8k.htm": {
   "nsprefix": "acad",
   "nsuri": "http://www.acadia-pharm.com/20240917",
   "dts": {
    "schema": {
     "local": [
      "acad-20240917.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "acad-20240917_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acad-20240917_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d861822d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2023": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-09-17_to_2024-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d861822d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-09-17_to_2024-09-17",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d861822d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.acadia-pharm.com//20240917/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-24-223726-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-223726-xbrl.zip
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M -0USO>O6;W_;T\'"=STY[Q2QN$4O\^=]_X9-FL'HGI3;GB[X*SA\_+]O(Z
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MO,J^I;:UOPD?L,QI^KOMA$ I"R(QH:9@@F/4!Z'P)P+"E2H[XW<8X 3L1HF
M;AX!^VVS[L01HZ6^,47/^C!P;":#%V,ZLI4]/!M!]1J2COGCK<U=?;RUS!XY
M]\BVT7.@N#?KQ]TDCF@V&\<[@)4'3LE"!S?AX3)Y' SR4,K0;>$\W3CZ W+<
M.Z[+AF!-(LL2 KT8>-HNQU 2[#F[OH>9.C:?@EPLPQX?S2W3M!\DN,-Y,<Z"
M38\3H(TS3$ 9*UA=>^ E! @M&'PO(]=&8!WO3KK@A[D"(D..H<7#O"^C$!!
MY[\-_ 6\)C1"DR&)=3.+)VUPE]SC6C, 43 5>"L6^R \>"MD-R[(:!:?= @^
MBA';82,EIPSC3%^:8&-M^9PG2IF)T0@U'D9PTM4"T9D#ZS8-<O"H=@Q7E5VJ
MJGY-$U61'@ Q8&K.IC1M# "Q:GEY?+0P??61H[CZ+/OSTQT,>CUC^4A YC%)
MV&?'IK1,PH*"#7(H$/X@X=50LW-^7P$10QD)TB0DRUL&XH??NO"M2S8SGW]E
MD+;AOP%2G!,E0.@1VFQQ@ 8BAX LO>5R9XK-<$F?Y;:SHY&R>##) "S^$T'@
M"1,VJGLL).H@+$$TQ7EP%;PCB@7<Y4JK-*C%&/+4H?0B[+LR;&3.="IL[.L"
ME?$A^E4QY@LL+0,H,2P<@UL&:0;7@J;GQ 5!T3U:?1.K.3NLT61T*4#,3@RU
M@5R*U!JOB L!N7LT,'<B($N&J&X[=_#JX<*KW>L/_0ZL*J9.- U>7D2OO7S,
M%C2.>).Q>10?DC4"TH"4I?*4F:F#AI%,4H&2)P-23;]9$.V\T6MI]Q(*I%28
M@SI>)+3E@$\!=?.%BS8=$R579V!T[X0J-F%["7%L.KH7%R^+H$=CGC'[(':8
MF2F;-(9L!*JX5ND"NND++6*BE1EDTY0#TKJQ_0!?0W>7N;IQ,<8\%4*C@ED!
M#?+ R7,WYB7L@?6(#S[8FMACH<LKL'/SB]%([1DG'"9!R#!G12]41&S*3_,>
M[6/5$_#&.R$%UVC&E%G@A:8?XZ,0BT[\*_5YDB3K'%EWDV:4."99DBYGF^.R
MYO;E%;:/;L$/T_Y1)<8284N\ X> 7'-[C.(6^8#Q@BZ8ME5\S3(QM!4% !#:
M87C7=O0&-D=?"RQ3.K8J$NF7Q_IV#E5;!)8"(F1Z;(LTC:.W(;2DYVH? ]^B
M7THNN4":H10K 9()6"97%:*LX<-1!&*%V4^9;(9/S;M:V7"%,.36!*:"L%.@
M#&'Q;^(,(>YJU*N-1VFSD3+4JA1D,<?*"9 1Z,<2C[?/-.K+T3K7> 'E\U "
M7HT%V\,W)(0D2OL*LF5K1K!I?&->-(;83T[WB&0.J><P)GG1FZ 9-7'[5'#/
M&-\UZ\S[O-+8'N5TA*RH-I?)QTVI?+AF/ SQ*I9,\)MU?6Q@[$I&EK"<.13P
M,660<>:&;ZB57=S-UJ_V>CUFQP*6,"OUP(N^Q_A<#V/+J1"Q+PMPHV,B73LI
M!+QP:(\[%E,9A!2IXY54TBV@"&%$B ^$A_'D_SGH+^;RJM_ ?"O 2"=R$(]_
MJ0ZJ90S?/R@'<(,G,\",#< <#X>XE: ST\M!$@?$<>_8E4.8:>A(?RX?3TO3
M]VBKP%]B7@!PL9^;=?WR$"('Y"XU-RFJ&P^C #0+3[](O"-<"-((YF+L3)#;
M#GW/\!#,2,+KR WPE%.)K!^"R("KYY:200!Y.%8IQP!"%T3!D7<\L"*8JDPS
M];![BIXOQ # \\81RD8'E,\E2T#22GLBFNXQ,@@DVRW7ZW4F]%%WH</7*?\W
M4![@LB-0$I=''EAM"G@@'0<_B#X<X)##(%21%OS)S ?OJ(",C@4#$.#I3/I@
M;68:8#^0RN&! P+W@:JS!%&!6@A7AXE);DTA98X\E-DG#&#@\27!K#?O I*%
MRX%A\SP+,_R2OE"F_PQ2-K)?^XODT,P DE*XHQQ-A_,(4 52?N8@)1K!+DBC
MS>,PR@@;:2'N>@"E*4+L"A="#3 @7\@XH6*X="-M,'%\^@@1&7H9"TPO:L(1
M;5/D\2(5D)66L=OI5V[+L5W\)*8\-*_.RU(9'+BB_46JT#LZ[L'/2OA1F)33
M$L71L,>5E@4=(ABJ>,136RN-G8=54,.??!/@HZ*#X<)KXXB5G^7$"^)=EE_X
MU#^.OTJ4^S-]_3D-]%.FDS1EB(Q*D#!6XY&8$*"&9BW0,]9FL*\0VI0U_XAA
M>)(M$<TA:7E&(C^#X0\ FXR*XNSL^LXP'-1#8+0 B&FHM4J..56M;"%\<)>X
M=461%=!V2E(-RY2Q "  %OT-!=YH;OHTSYE& /V(\CC^3H&'=9($5]S+(#[-
MUQ[II4MAT]^WPIH8H -=W:OF,FDHQMS+8H,;RQH*8T*\:,2M4&L#H-K!';Q_
M@>A;W&03P%U/&\@/ ZN*$QBX9GHULFL([A>/S"9F0Z3HI $A6J"A &W6<Z1Q
MJI%"\ 0(B9YKOO#5ES- =8$* VDY&-9N7_9O)H,=@W(W4A#@AN[L$7<58":+
M\P[CTJB=5OA'$&0[,EBL]]+96Y0XYD=#B#TAX"8Y3?P.$K$3@+T,^P\T3#EW
MNLZ2'9?/G'M0T1&=QW1GC\"&2T PY"1TL>(=A-BOX1$HRB;8-:00G@37=7/1
M3:%&745+"F0K\I]4?>8K2-27P)V0_5-"JAEK=H;KGV3@8XB.D>IJ8X<_>@'V
M$A*\I"5 @; Z_R6\EN*=3"R3S3&*6\NR^Y5;V0W++;;UO[UG^5*7HN27AY<%
M/_&X/)/'/9[*E!^OU5$<0-.DJ7+1ZG,EJ+PWL\X),V)3(B%=73CAFM7$=EHT
MQB*UCN:SU6!0H)^/ZG6*7+"E#?UFMKPK@).09+NH2H!77"U/)X.7J(6$*N=4
MX=4]$G'5ET^IU)/4J _K[V*3L0Q..2V%98K)*[46B%&A"E*LM%B-U\LC>1[C
M-AIA1WM*G?CJ6O,:I@+W1BIX)Y9>TN>S./7_>4\3=*[8O\:,!@V>''-P^?V0
M6U_C$$E?R9LG/7JG!LRAZ>^"=1#QW] F]@5'DRAU_"!2V9HOD.+X]?;$YDMQ
M.]GB7S@!<36Q5RJ0!'N2YMKFIF%J=,F1]')2ML^50-JEQ+I *(HVZ8Q<+15/
M]>; &)N!* AQ/$^7)"G7+7"'6.,%[Y&*?ES) \&'!<#'F,0G*0QBN1O[:6-U
M#R?H^R:872KT;[3=80J<)F//YBIY&!4:(&!5)C>&F77-;CB_@YGXY3,'\D"Z
MRDW'"!#IS0(L5*9= WG+ [@/,T8W\Q"O4%804]+1CJ;V95HB&&1*!'A</]ZU
M7:BF4, <5U322^;0VU/^:4I2^V63B+Y&\=.43I#?=,W!G; 7K*NIJ1?8E=@\
MWV,"09*F"Q+%.[/MXICBN4?M_HI]/WOOBEN%S2&8-1J#R%ON%TZ1WUNTO.Z+
M]@>M2?ZE=J".9PQ97(QCTM=U"+2.D0*%0G^*K>E!D4);NKE=OS[OKW67.WJQ
MW7)SS_@Q(]1H"VF_I[GW+@[*5WHUZ8D*>H3$-WLZ.#?1!\Y!BJ(=@TY"3;A
M>[;NC/::P&Z:AJ0[4YC-.AOT>X)2PSFGFV?1TQVZC"^$N60TGL3WFT!Z0HH4
M;T@A:,$Q ?>*1V5_Z._?77^SP3-IK*X7/44EC5JD*I%1 [W/2D7!.$:-HYA0
MAEAMP[6UQX90(HR4QP YF!:4%Z-+EU/806$LS!N(Q9W\-%00H-HFC(>06$:
M#783HA9146:EO:A7&GOU=]F.?)-(@/(]KMH9\_9$%?^VSL:-A1V!B,.*N;@A
MW8/*V9MIL9YG1_I<M&E! @*A""TP7K<X4+TFW7$.=&J$71#>(D4\&6)&A)3'
M5U?%Q=@ 02&Z*PKB\\56J?DFEP2ICMY$BULP0TI+]#U@.!/^^J.2;E'?G6G
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ME-H-2>L#;13@KFAI91ZR=;RZ$9[^2%3PS!'* =QI*>EV'*81:,>"(=H$5/)
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M8V&C!]N'<P!3RI:WT*A=<2&2&,0-7.XLX0A//--Z"H%$&%U'82GBW$UGI!/
M?*S C,0J<I)>$%])EJLTM41C1YZYQ*-:, %G*T1:$-<JKG,241TTO$^)NU!!
MYJZ"7</F_##K8R';+))HQNH48+^L^:-P:'D1:(U+4)%<!=P8ZU'OI"UEX&!!
M+45*"".*E.8@:.\4BA'7:11J@0W3<@*KVV3#.FX.;B%6I(GUZ4Q6'1/7,\)?
MI$0299*4 B)"I]F52*)_JW/C2 MN..+# B6$H#)O\+^3*YW+ 6;F T<7,J*-
MWI!M5%8"OD>'!)',C""9RRHVS:("Q\;D/!2EW">J<F"C*OWAA\%YE\(J%^_
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M^J+(RR_59BI@MMU.<%:$\+^C,@$1AKLW]UL-L-J@)^,8JR4PVP:JAR[!9R2
M1[X&9]$,K+1Y\AA.92Z"W\"[I:)6^ $E7FFE(%.PJ%$:RR15=RLEW@TEZ8,
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MV-O&$*V'$!!/3/,*5T3YA-C/M2KP_+! D3&&W4E0M" Y G$,$.<=7)'K_ZD
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M?L!+  /W\O1/^.&[V]_/C_X/4$L! A0#%     @ 3H0W663A#+,^ P  60L
M !$              ( !     &%C860M,C R-# Y,3<N>'-D4$L! A0#%
M  @ 3H0W615:JOM_!@  ND8  !4              ( !;0,  &%C860M,C R
M-# Y,3=?;&%B+GAM;%!+ 0(4 Q0    ( $Z$-UE;-(?XR@0  $@L   5
M          "  1\*  !A8V%D+3(P,C0P.3$W7W!R92YX;6Q02P$"% ,4
M" !.A#=9LZV5>PP;  !CD@  #@              @ $<#P  9#@V,3@R,F0X
M:RYH=&U02P$"% ,4    " !.A#=9&PYB2!8I  "2IP  $0
M@ %4*@  9#@V,3@R,F1E>#$P,2YH=&U02P$"% ,4    " !.A#=9-;"-_)0E
M  "AG   $0              @ &94P  9#@V,3@R,F1E>#$P,BYH=&U02P4&
2      8 !@!_ 0  7'D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d861822d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="acad-20240917.xsd" xlink:type="simple"/>
    <context id="duration_2024-09-17_to_2024-09-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001070494</identifier>
        </entity>
        <period>
            <startDate>2024-09-17</startDate>
            <endDate>2024-09-17</endDate>
        </period>
    </context>
    <dei:EntityRegistrantName
      contextRef="duration_2024-09-17_to_2024-09-17"
      id="Hidden_dei_EntityRegistrantName">ACADIA PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-314">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-09-17_to_2024-09-17"
      id="Hidden_dei_EntityCentralIndexKey">0001070494</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-325">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-326">2024-09-17</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-327">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-328">000-50768</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-329">06-1376651</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-330">12830 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-331">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-332">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-333">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-334">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-335">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-336">558-2871</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-337">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-338">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-339">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-340">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-341">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-342">ACAD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-343">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-09-17_to_2024-09-17" id="ixv-344">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
